As the Health Service Executive prepares to reap financial savings from a predicted increase in biosimilar usage, the European Commission has approved three new therapies indicated for the treatment of breast cancer, metastatic colorectal cancer, and non-Hodgkin’s lymphoma, respectively, Peter Doyle reports With the European Medicines Agency approving the use of more than 50 biosimilars
The post A trio of drugs to boost biosimilars use appeared first on Irish Medical Times.